### SUBPART 5—DEFINITIONS AND MISCELLANEOUS PROVISIONS

### §1395w–151. Definitions; treatment of references to provisions in part C
#### (a) Definitions
* For purposes of this part:

* #### (1) Basic prescription drug coverage
  * The term "basic prescription drug coverage" is defined in section 1395w–102(a)(3) of this title.

* #### (2) Covered part D drug
  * The term "covered part D drug" is defined in section 1395w–102(e) of this title.

* #### (3) Creditable prescription drug coverage
  * The term "creditable prescription drug coverage" has the meaning given such term in section 1395w–113(b)(4) of this title.

* #### (4) Part D eligible individual
  * The term "part D eligible individual" has the meaning given such term in section 1395w–101(a)(3)(A) of this title.

* #### (5) Fallback prescription drug plan
  * The term "fallback prescription drug plan" has the meaning given such term in section 1395w–111(g)(4) of this title.

* #### (6) Initial coverage limit
  * The term "initial coverage limit" means such limit as established under section 1395w–102(b)(3) of this title, or, in the case of coverage that is not standard prescription drug coverage, the comparable limit (if any) established under the coverage.

* #### (7) Insurance risk
  * The term "insurance risk" means, with respect to a participating pharmacy, risk of the type commonly assumed only by insurers licensed by a State and does not include payment variations designed to reflect performance-based measures of activities within the control of the pharmacy, such as formulary compliance and generic drug substitution.

* #### (8) MA plan
  * The term "MA plan" has the meaning given such term in section 1395w–101(a)(3)(B) of this title.

* #### (9) MA–PD plan
  * The term "MA–PD plan" has the meaning given such term in section 1395w–101(a)(3)(C) of this title.

* #### (10) Medicare Prescription Drug Account
  * The term "Medicare Prescription Drug Account" means the Account created under section 1395w–116(a) of this title.

* #### (11) PDP approved bid
  * The term "PDP approved bid" has the meaning given such term in section 1395w–113(a)(6) of this title.

* #### (12) PDP region
  * The term "PDP region" means such a region as provided under section 1395w–111(a)(2) of this title.

* #### (13) PDP sponsor
  * The term "PDP sponsor" means a nongovernmental entity that is certified under this part as meeting the requirements and standards of this part for such a sponsor.

* #### (14) Prescription drug plan
  * The term "prescription drug plan" means prescription drug coverage that is offered—

    * (A) under a policy, contract, or plan that has been approved under section 1395w–111(e) of this title; and

    * (B) by a PDP sponsor pursuant to, and in accordance with, a contract between the Secretary and the sponsor under section 1395w–112(b) of this title.

* #### (15) Qualified prescription drug coverage
  * The term "qualified prescription drug coverage" is defined in section 1395w–102(a)(1) of this title.

* #### (16) Standard prescription drug coverage
  * The term "standard prescription drug coverage" is defined in section 1395w–102(b) of this title.

* #### (17) State Pharmaceutical Assistance Program
  * The term "State Pharmaceutical Assistance Program" has the meaning given such term in section 1395w–133(b) of this title.

* #### (18) Subsidy eligible individual
  * The term "subsidy eligible individual" has the meaning given such term in section 1395w–114(a)(3)(A) of this title.

#### (b) Application of part C provisions under this part
* For purposes of applying provisions of part C under this part with respect to a prescription drug plan and a PDP sponsor, unless otherwise provided in this part such provisions shall be applied as if—

  * (1) any reference to an MA plan included a reference to a prescription drug plan;

  * (2) any reference to an MA organization or a provider-sponsored organization included a reference to a PDP sponsor;

  * (3) any reference to a contract under section 1395w–27 of this title included a reference to a contract under section 1395w–112(b) of this title;

  * (4) any reference to part C included a reference to this part; and

  * (5) any reference to an election period under section 1395w–21 of this title were a reference to an enrollment period under section 1395w–101 of this title.

### §1395w–152. Miscellaneous provisions
#### (a) Access to coverage in territories
* The Secretary may waive such requirements of this part, including section 1395w–103(a)(1) of this title, insofar as the Secretary determines it is necessary to secure access to qualified prescription drug coverage for part D eligible individuals residing in a State (other than the 50 States and the District of Columbia).

#### (b) Application of demonstration authority
* The provisions of section 402 of the Social Security Amendments of 1967 (Public Law 90–248) shall apply with respect to this part and part C in the same manner it applies with respect to parts A and B, except that any reference with respect to a Trust Fund in relation to an experiment or demonstration project relating to prescription drug coverage under this part shall be deemed a reference to the Medicare Prescription Drug Account within the Federal Supplementary Medical Insurance Trust Fund.

#### (c) Coverage gap rebate for 2010
* #### (1) In general
  * In the case of an individual described in subparagraphs (A) through (D) of section 1395w–114a(g)(1) of this title who as of the last day of a calendar quarter in 2010 has incurred costs for covered part D drugs so that the individual has exceeded the initial coverage limit under section 1395w–102(b)(3) of this title for 2010, the Secretary shall provide for payment from the Medicare Prescription Drug Account of $250 to the individual by not later than the 15th day of the third month following the end of such quarter.

* #### (2) Limitation
  * The Secretary shall provide only 1 payment under this subsection with respect to any individual.

#### (d) Treatment of certain complaints for purposes of quality or performance assessment
* In conducting a quality or performance assessment of a PDP sponsor, the Secretary shall develop or utilize existing screening methods for reviewing and considering complaints that are received from enrollees in a prescription drug plan offered by such PDP sponsor and that are complaints regarding the lack of access by the individual to prescription drugs due to a drug management program for at-risk beneficiaries.

### §1395w–153. Condition for coverage of drugs under this part
#### (a) In general
* In order for coverage to be available under this part for covered part D drugs (as defined in section 1395w–102(e) of this title) of a manufacturer, the manufacturer must—

  * (1) participate in the Medicare coverage gap discount program under section 1395w–114a of this title;

  * (2) have entered into and have in effect an agreement described in subsection (b) of such section with the Secretary; and

  * (3) have entered into and have in effect, under terms and conditions specified by the Secretary, a contract with a third party that the Secretary has entered into a contract with under subsection (d)(3) of such section.

#### (b) Effective date
* Subsection (a) shall apply to covered part D drugs dispensed under this part on or after January 1, 2011.

#### (c) Authorizing coverage for drugs not covered under agreements
* Subsection (a) shall not apply to the dispensing of a covered part D drug if—

  * (1) the Secretary has made a determination that the availability of the drug is essential to the health of beneficiaries under this part; or

  * (2) the Secretary determines that in the period beginning on January 1, 2011, and December 31, 2011, there were extenuating circumstances.

#### (d) Definition of manufacturer
* In this section, the term "manufacturer" has the meaning given such term in section 1395w–114a(g)(5) of this title.

### §1395w–154. Improved Medicare prescription drug plan and MA–PD plan complaint system
#### (a) In general
* The Secretary shall develop and maintain a complaint system, that is widely known and easy to use, to collect and maintain information on MA–PD plan and prescription drug plan complaints that are received (including by telephone, letter, e-mail, or any other means) by the Secretary (including by a regional office of the Department of Health and Human Services, the Medicare Beneficiary Ombudsman, a subcontractor, a carrier, a fiscal intermediary, and a Medicare administrative contractor under section 1395kk–1 of this title) through the date on which the complaint is resolved. The system shall be able to report and initiate appropriate interventions and monitoring based on substantial complaints and to guide quality improvement.

#### (b) Model electronic complaint form
* The Secretary shall develop a model electronic complaint form to be used for reporting plan complaints under the system. Such form shall be prominently displayed on the front page of the Medicare.gov Internet website and on the Internet website of the Medicare Beneficiary Ombudsman.

#### (c) Annual reports by the Secretary
* The Secretary shall submit to Congress annual reports on the system. Such reports shall include an analysis of the number and types of complaints reported in the system, geographic variations in such complaints, the timeliness of agency or plan responses to such complaints, and the resolution of such complaints.

#### (d) Definitions
* In this section:

* #### (1) MA–PD plan
  * The term "MA–PD plan" has the meaning given such term in section 1395w–151(a)(9) of this title.

* #### (2) Prescription drug plan
  * The term "prescription drug plan" has the meaning given such term in section 1395w–151(a)(14) of this title.

* #### (3) Secretary
  * The term "Secretary" means the Secretary of Health and Human Services.

* #### (4) System
  * The term "system" means the plan complaint system developed and maintained under subsection (a).